# 510(k) SUMMARY

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirement of SMDA 1990 and 21 CFR 807.92.

# VIDAS® Lyme IgM

# A. Submitter Information

Submitter's Name: Address:

bioMérieux SA   
Chemin de I'Orme   
69280 Marcy-I'Etoile - France   
Catherine FRITSCH   
$+ 3 3$ 4 78 87 23 98   
$\yen 33$ 4 78 87 20 75   
August 2012

Contact Person: Phone Number: Fax Number: Date of Preparation:

# B. Device Name

Trade Name: Common Name: Classification Name:

VIDAS® Lyme IgM   
Lyme IgM Assay   
21 CFR 866.3830 - Treponema pallidum treponemal test   
reagents

# C. Predicate Device Name

Trade Name: PlateliaT Lyme IgM

D. Device Description

The VIDAS Lyme IgM assay principle combines a 2-step enzyme immunoassay sandwich method with a final fluorescent detection (ELFA) (see User's Manual).

The Solid Phase Receptacle (SPR®) serves as the solid phase as well as the pipetting device for the assay. Reagents for the assay are ready-to-use and predispensed in the sealed reagent strips.

All of the assay steps are performed automatically by the instrument. The reaction medium is cycled in and out of the SPR several times.

After a preliminary wash step and a sample dilution step, the antibodies to B. burgdorferi present in the specimen will bind to the B. burgdorferi specific recombinant proteins coating the interior of the SPR.

Unbound sample components are washed away. Anti-human IgM antibodies conjugated with alkaline phosphatase, will attach to the immunocomplex bound to the SPR wall.

A final wash step removes unbound conjugate. During the final detection step, the substrate (4-Methyl-umbelliferyl phosphate) is cycled in and out of the SPR. The conjugate enzyme catalyzes the hydrolysis of this substrate into a fluorescent product (4-Methyl-umbelliferone) the fluorescence of which is measured at 450 nm. The intensity of the fluorescence is proportional to the quantity of anti-B. burgdorferi IgM antibody present in the sample.

At the end of the VIDAS Lyme IgM assay, results are automatically calculated by the instrument. A test value is generated and a report is printed.

# E. Intended Use

The VIDAS Lyme IgM (LYM) assay is an automated qualitative enzyme immunoassay intended for use on the instruments of the VIDAS family in the presumptive detection of human IgM antibodies to Borrelia burgdorferi in human serum (plain or separation gel) or plasma (sodium heparin or lithium heparin). It should be used to test patients with a history and/or symptoms of infection with B. burgdorferi. All VIDAS Lyme IgM positive and equivocal specimens should be further tested with a Western Blot IgM assay to obtain supportive evidence of infection with B. burgdorferi.

# F. Technological Characteristics Summary

A general comparison of the similarities and differences of the assays is presented in the table below.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>VIDAS® Lyme IgM (LYM) Assay</td><td rowspan=1 colspan=1>Platelia ™ Lyme IgM (K081362)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The VIDAS Lyme IgM (LYM) assayis an automated qualitative enzymeimmunoassay intended for use onthe instruments of the VIDAS familyin the presumptive detection ofhuman IgM antibodies to Borreliaburgdorferi in human serum (plain orseparation gel) or plasma (sodiumheparin or lithium heparin). It shouldbe used to test patients with ahistory and/or symptoms of infectionwith B. burgdorferi. All VIDAS LymeIgM   positive   and   equivocalspecimens should be further testedwith a Western Blot IgM assay toobtainsupportiveevidence ofinfection with B. burgdorferi.</td><td rowspan=1 colspan=1>The Platelia™M Lyme IgM Test is aqualitative test intended for use inthe presumptive detection ofhuman IgM antibodies to Borreliaburgdorferi in human serum orplasma (K3EDTA, sodiumheparin or sodium citrate). TheEIA system should be used to testserum or plasma from patientswith a history and symptoms ofinfection with Borrelia burgdorferi.All  positive   and  equivocalspecimens should be re-testedwith a specific, second-tier testsuch as Western-Blot. Positivesecond-tier results are supportiveevidence of infection with Borreliaburgdorferi. The diagnosis ofLyme disease should be madebased on history and symptoms(such as erythema migrans), andother laboratory data, in additionto the presence of antibodies toBorreliaburgdorferi.Negative   results(either first- or second-tier) shouldnot be used to exclude Lymedisease.</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Serum or plasma</td><td rowspan=1 colspan=1>Serum or plasma</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>IgM antibodies to Borrelia burgdorferi</td><td rowspan=1 colspan=1>IgM antibodies to Borreliaburgdorferi</td></tr><tr><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>AssayTechnique</td><td rowspan=1 colspan=1>Enzyme-linked fluorescent assay(ELFA)</td><td rowspan=1 colspan=1>Enzyme immunoassay (EIA)</td></tr></table>

# G. Nonclinical Tests

A summary of the non-clinical results is presented below.

# Precision

For the precision study, 4 serum samples were tested in duplicate in 40 different runs (2 runs per day over 20 days) with 2 reagent lots at $\uparrow$ site $( \mathsf { n } = 8 0 )$ The precision was calculated following the recommendations of the $\mathsf { C L S I } ^ { \otimes }$ document EP5-A2. The total precision data in the table reflect the 80 values generated per sample for Site 1 and takes into account replicate, run, day, calibration, and lot as potential sources of variation. The total precision for controls include within-day, between-days and between-calibration variability and is lot specific.

<table><tr><td rowspan=2 colspan=1>Panel Member</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>MeanIndex</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Within-day</td><td rowspan=1 colspan=2>Between-days</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0.</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td></tr></table>

# Reproducibility

For reproducibility, 4 serum samples were tested in duplicate in 40 different runs (2 runs per day over 20 days) with 2 reagent lots at 3 sites $( n = 2 4 0 )$ . The reproducibility was calculated following the recommendations of the $\cot \tt S l ^ { \otimes }$ document EP5-A2. The total reproducibility data in the table reflects the 240 values generated per sample for all sites and takes into account replicate, run, day, calibration, lot, and site as potential sources of variation. Out of the 240 total values, 2 Low Positives (Sample 3) gave an equivocal value $( < 0 . 3 2 )$ . The total reproducibility for controls include within-day, between-days, between-calibration and between-site variability and is lot specific.

<table><tr><td colspan="1" rowspan="2">PanelMember</td><td colspan="1" rowspan="2">N</td><td colspan="1" rowspan="2">MeanIndex</td><td colspan="2" rowspan="1">Within-run</td><td colspan="2" rowspan="1">Within-day</td><td colspan="2" rowspan="1">Between-days</td><td colspan="2" rowspan="1">Between-site</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td></tr><tr><td colspan="1" rowspan="1">Sample1</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">6.3</td></tr><tr><td colspan="1" rowspan="1">Sample2</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">7.8</td></tr><tr><td colspan="1" rowspan="1">Sample3</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">6.2</td></tr><tr><td colspan="1" rowspan="1">Sample4</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">1.26</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">9.4</td></tr><tr><td colspan="1" rowspan="1">PositiveControl</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">12.1</td></tr><tr><td colspan="1" rowspan="1">NegativeControl</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00:</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td></tr></table>

# Interfering Substances

# Specimen-related interference

Interferences were studied according to the recommendations of $\cos 1 \sin$ document EP7-A2. None of the following factors have been found to significantly influence this assay:

hemolysis (after spiking samples with hemoglobin: $5 9 1 L$ (monomer)), lipemia (after spiking samples with lipids: $3 0 \seteq I L$ equivalent in triglycerides), bilirubinemia (after spiking samples with bilirubin: $\begin{array} { r } { 0 . 3 \mathfrak { g } / \mathfrak { L } . } \end{array}$ human albumin (after spiking samples with albumin up to ${ \tt6 0 } { \tt g } / { \tt L }$

It is recommended not to use samples that are clearly hemolyzed, lipemic or icteric and, if possible, to collect a new sample.

Exogenous Interferents: Following the recommendations of $\mathsf { C L S l } ^ { \otimes }$ document EP7-A2, the potential interferences with 15 commonly used drugs were studied. No interference was observed at the concentration tested.

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration tested</td><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentrationtested</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>3.62 mmol/L</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>2425 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>206 μmol/L</td><td rowspan=1 colspan=1>Minocycline</td><td rowspan=1 colspan=1>4.1 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Azithromycin</td><td rowspan=1 colspan=1>34 μmol/L</td><td rowspan=1 colspan=1>Penicillin G</td><td rowspan=1 colspan=1>240 000 U/L</td></tr><tr><td rowspan=1 colspan=1>Betamethasone</td><td rowspan=1 colspan=1>8.31 μmol/L</td><td rowspan=1 colspan=1>PenicillinPhenoxymethyl</td><td rowspan=1 colspan=1>30 000 U/L</td></tr><tr><td rowspan=1 colspan=1>Ceftriaxone</td><td rowspan=1 colspan=1>1460 μmol/L</td><td rowspan=1 colspan=1>Prednisolone</td><td rowspan=1 colspan=1>8.31 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Cefuroxime axetil</td><td rowspan=1 colspan=1>1416 μmol/L</td><td rowspan=1 colspan=1>Roxithromycin</td><td rowspan=1 colspan=1>15.3 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Doxycycline hyclate</td><td rowspan=1 colspan=1>16.1 μmol/L</td><td rowspan=1 colspan=1>Tetracyclines</td><td rowspan=1 colspan=1>67.5 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>22.2 µmol/L</td><td rowspan=1 colspan=2>,</td></tr></table>

# H.Clinical Testing

# Sensitivity testing

202 retrospective samples from patients meeting a case definition of LD and confirmed positive for B. Burgdorferi infection were run on the VIDAS Lyme IgM assay and the predicate Lyme IgM assay.

For both he VIDAS Lyme IgM and he predicate st, equivocal results were considerd as positive for the evaluation. The following results were obtained:

<table><tr><td rowspan=1 colspan=1>Stage</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>VIDAS Lyme IgM% Sensitivity *</td><td rowspan=1 colspan=1>Predicate LymeIgM% Sensitivity *</td><td rowspan=1 colspan=1>Difference inproportions</td></tr><tr><td rowspan=1 colspan=1>Stage Iearlylocalized,single lesion)1 - 30 days</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>52.1 (62/119)95% CI [42.8 -61.3]%</td><td rowspan=1 colspan=1>54.6 (65/119)95% CI [45.2 -63.%</td><td rowspan=1 colspan=1>-2.5%95% CI [(-15.2)% -(10.2)%]</td></tr><tr><td rowspan=1 colspan=1>Stage Ⅱ(earlydisseminated,multiplelesions)1 - 30 days</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>91.9 (57/62)95% CI [82.2 -97.3%</td><td rowspan=1 colspan=1>91.9 (57/62)95% CI [82.2 97.3]%</td><td rowspan=1 colspan=1>0.0%95% CI (-9.6)% -(9.6)%</td></tr><tr><td rowspan=1 colspan=1>Stage III(latedisseminated)</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>76.2 (16/21)95% CI [52.8 -91.8%</td><td rowspan=1 colspan=1>61.9 (13/21)95% CI [38.4 -81.9]%</td><td rowspan=1 colspan=1>14.3%95% CI [(-13.3)% -(41.9)%]</td></tr><tr><td rowspan=1 colspan=1>All stages</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>66.8 (135/202)95% CI [59.9 -73.3]%</td><td rowspan=1 colspan=1>66.8 (135/202)95% CI [59.9 -73.3]%</td><td rowspan=1 colspan=1>0.0%95% CI (-9.2)% -(9.2)%</td></tr></table>

\* includes positive and equivocal results.

# Method Comparison

A prospective study was performed on 975 fresh or frozen prospectively collected sera submitted for routine Lyme disease testing from an endemic area of the United States. Testing was performed in three laboratories.

At each laboratory, the samples were tested in parallel using a commercially available Lyme IgM EIA method (predicate) and the VIDAS Lyme IgM assay. Positive $\%$ Agreement (PPA) is calculated for the positives and equivocals together since the 2-tier testing does not make a distinction and calls for both of them to be tested by Western Blot. Combined results from the three sites are shown below.

<table><tr><td rowspan=1 colspan=1>N = 975</td><td rowspan=1 colspan=3>Predicate Lyme IgM</td></tr><tr><td rowspan=1 colspan=1>VIDAS Lyme IgM</td><td rowspan=1 colspan=1>pslld</td><td rowspan=1 colspan=1>Bn</td><td rowspan=1 colspan=1>Negelae</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>678</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>765</td></tr><tr><td rowspan=1 colspan=1>Positive % Agreement95% CI</td><td rowspan=1 colspan=3>51.0% (107/210)[44.0 - 57.9]%</td></tr><tr><td rowspan=1 colspan=1>Negative % Agreement95% CI</td><td rowspan=1 colspan=3>88.6% (678/765)[86.2 - 90.8]%</td></tr></table>

Second-Tier Testing: In accordance with the CDC recommendations for use of a 2-tier Lyme disease testing scheme, the VIDAS Lyme IgM positive and equivocal results and the predicate Lyme IgM positive and equivocal results were confirmed using a commercially available Lyme IgM Western Blot method.

The percent agreement between VIDAS and predicate Lyme IgM positives ( $1 ^ { s t }$ tier PPA) and the percent agreement between VIDAS-predicate-Western Blot IgM positives and Predicate—Western Blot IgM positives $( 2 ^ { n d }$ tier PPA) are shown below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>$1$$ier+ or ±</td><td rowspan=1 colspan=1>IgM WesternPos.            Neg.</td></tr><tr><td rowspan=1 colspan=1>Predicate IgM</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>104            106</td></tr><tr><td rowspan=1 colspan=1>VIDAS IgM</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>95            93*</td></tr><tr><td rowspan=1 colspan=1>VIDASIgMandPredicateIgM</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>84          ·23</td></tr></table>

W      l p

Agreement results: 11 Tier $\mathsf { P P A } = 5 1 . 0 \%$ (107/210), 95% CI=[44.0% - 57.9%] $2 ^ { n d }$ Tier $p \mathsf { P A } = 8 0 . 8 \%$ (84/104), 95% Cl=[72.2% - 87.2%]

Concordance with IgM Western Blot: Predicate device: $4 9 . 5 \%$ (104/210) VIDAS Lyme IgM: $4 9 . 0 \%$ (95/194)

# Analytical Specificity

100 sera from apparently healthy subjects from an endemic population (New York) and 100 sera from a non-endemic population (Texas) with no known history of Lyme disease were run on the VIDAS Lyme IgM assay and the predicate Lyme IgM assay. The following results were obtained:

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>VIDAS</td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=1>Positivity*</td><td rowspan=1 colspan=1>Negativity</td><td rowspan=1 colspan=1>Positivity</td><td rowspan=1 colspan=1>Negativity</td></tr><tr><td rowspan=1 colspan=1>Endemic</td><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>88.0%</td><td rowspan=1 colspan=1>19.0%</td><td rowspan=1 colspan=1>81.0%</td></tr><tr><td rowspan=1 colspan=1>Non-Endemic</td><td rowspan=1 colspan=1>14.0%</td><td rowspan=1 colspan=1>86.0%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>97.0%</td></tr></table>

\* Includes positives and equivocals.

# CDC Reference Panel

The following information is from a serum panel obtained from the CDC and tested using the VIDAS Lyme IgM kit. The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This does not imply an endorsement of the assay by the CDC.

<table><tr><td rowspan=2 colspan=1>Timefromonset</td><td rowspan=1 colspan=3>VIDAS Lyme IgM</td><td rowspan=1 colspan=3>Western blot IgM</td></tr><tr><td rowspan=1 colspan=1>Positiveorequivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Agreementwith clinicalstatus</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Agreementwith clinicalstatus</td></tr><tr><td rowspan=1 colspan=1>Normals</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80.0 %(4/5)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.0 %(5/5)</td></tr><tr><td rowspan=1 colspan=1>&lt; 1 month</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>60.0 %(3/5)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>60.0 %(3/5)</td></tr><tr><td rowspan=1 colspan=1>1-2months</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>83.3 %(5/6)</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>83.3 %(5/6)</td></tr><tr><td rowspan=1 colspan=1>3- 12months</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75.0 %(12/16)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>43.8 %(7/16)</td></tr><tr><td rowspan=1 colspan=1>&gt; 1 year</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>42.9 %(3/7)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>42.9 %(3/7)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>69.2%(27/39)</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>59.0 %(23/39)</td></tr></table>

# Cross-Reactivity

Cross-reactivity is based on the study of samples that are negative with the test being evaluated and positive for the potentially interfering disease. The results of the samples tested according to the disease are shown in the table below:

<table><tr><td rowspan=1 colspan=1>Infection or Diagnosis</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>VIDAS LymeIgMEquivocal orpositiveresults</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Anti Nuclear Antibodies</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.00</td></tr><tr><td rowspan=1 colspan=1>C Reactive Protein</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6.55</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>17.64</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10.76</td></tr><tr><td rowspan=1 colspan=1>Helicobacter pylori</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6.99</td></tr><tr><td rowspan=1 colspan=1>Hepatitis A Virus</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>14.37</td></tr><tr><td rowspan=1 colspan=1>HerpesSimplex Virus</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15.30</td></tr><tr><td rowspan=1 colspan=1>Human Immunodeficiency Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>35.00</td></tr><tr><td rowspan=1 colspan=1>Human Anti-mouse Antibodies</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6.45</td></tr><tr><td rowspan=1 colspan=1>Leptospirosis</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>10.18</td></tr><tr><td rowspan=1 colspan=1>Measles</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>13.15</td></tr><tr><td rowspan=1 colspan=1>Mumps</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.34</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.19</td></tr><tr><td rowspan=1 colspan=1>Rickettsiosis</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>5.35</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10.52</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>9.25</td></tr><tr><td rowspan=1 colspan=1>Systemic Lupus Erythematosus</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.14</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>19.23</td></tr><tr><td rowspan=1 colspan=1>Varicella Zoster Virus</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6.89</td></tr></table>

The effect of Babesiosis, Erhlichiosis and Rocky Mountain spotted fever pathologiesn te VIDAS Lyme IgM performance is not known.

# . Conclusion

The results from the nonclinical and clinical studies submitted in this premarket notification are complete and demonstrate that the ViDAS® Lyme IgM is substantially equivalent to the predicate device identified in Item C of this summary.

bioMerieux SA c/o Catherine FRITSCH Regulatory Affairs Director 5 rue des Aqueducs 69290 Craponne, France

Re: K122979 Trade/Device Name: VIDAS $\textsuperscript { \textregistered }$ Lyme IgM Regulation Number: 21 CFR 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: Class I Product Code: LSR Dated: May 6, 2013 Received: May 7, 2013

Dear Ms. FRITSCH:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. andCosmeticAct (Act)that donot'requireapprovalofa'premarketapprovalapplication(PMA):

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class ⅡI (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours, Uwe Scherf -S for

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K122979

Device Name: VIDAS® Lyme IgM

Indications For Use:

The VIDAS Lyme IgM (LYM) assay is an automated qualitative enzyme immunoassay intended for use on the instruments of the VIDAS family in the presumptive detection of human IgM antibodies to Borrelia burgdorferi in human serum (plain or separation gel) or plasma (sodium heparin or lithium heparin). It should be used to test patients with a history and/or symptoms of infection with B. burgdorferi. All VIDAS Lyme IgM-positive and equivocal specimens should be further tested with a Western Blot IgM assay to obtain supportive evidence of infection with B. burgdorferi.

Prescription Use X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

John-HobsonS Division Sign-Off 2013.0603)13:35:34 Offic inViDignostics and RadiologicalHeath -0400 51010 K122979